BioDirection Inc Information

BioDirection, Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company’s lead product, the Tbit™ blood test, delivers biologically based results shown to confirm a concussion accurately in less than 90 seconds. BioDirection’s platform utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics. n most cases, concussion or mild traumatic brain injury is diagnosed based on a range of subjective, symptom-based tests that are frequently inconclusive. The lack of a rapid, objective diagnostic tool means that a significant percentage of brain injuries go undiagnosed or are diagnosed inaccurately each year. An objective point-of-care system able to diagnose traumatic brain injury in minutes at the time of injury could have significant benefits, potentially leading to faster and more appropriate treatment. Tbit™ is not FDA approved and currently for research use only.